|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
a Biotie Therapies Corp., Turku, Finland
Key Words: vascular adhesion protein-1 (VAP-1) • copper-containing amine oxidase • semicarbazide-sensitive amine oxidase (SSAO) • adhesion molecule • leukocyte trafficking • inflammation • autoimmune disease
Address for correspondence: David Smith, Biotie Therapies Corp., Tykistökatu 6, Turku, FIN-20520, Finland. Voice: +358-22748922; fax: +358-22748910. david.smith{at}biotie.com
The development of new, safe, and effective anti-inflammatory drugs represents a major challenge for the pharmaceutical industry, as well as a significant opportunity. The increasing prevalence of chronic inflammatory and autoimmune diseases associated with an aging population has led to an intense effort to discover new anti-inflammatory drug targets and drugs acting against them. This review highlights the recent progress made in developing therapies directed against an endothelial cell adhesion molecule called vascular adhesion protein (VAP)-1 for the treatment of chronic inflammatory disease as well as highlighting other therapeutic opportunities offered by this vascular target.
|
 |
 |
